Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy

CD19-directed CAR T-cells have been remarkably successful in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and transformed follicular lymphoma (t-FL). In this cohort study, we treated 60 patients with axicabtagene ciloleucel or tisagenlecleucel. Complete and...

Full description

Bibliographic Details
Main Authors: Sylvain Lamure, François Van Laethem, Delphine De Verbizier, Claire Lozano, Eve Gehlkopf, Jean-Jacques Tudesq, Chris Serrand, Mehdi Benzaoui, Tarik Kanouni, Adeline Quintard, John De Vos, Emmanuelle Tchernonog, Laura Platon, Xavier Ayrignac, Patrice Ceballos, Anne Sirvent, Mickael François, Hanane Guedon, Philippe Quittet, Cedric Mongellaz, Aurélie Conte, Charles Herbaux, Caroline Bret, Naomi Taylor, Valérie Dardalhon, Guillaume Cartron
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
CAR T-cell
axicabtagene ciloleucel
tisagenleucleucel
diffuse large B-cell lymphoma
standard-of-care
immune-monitoring
Online Access:https://www.mdpi.com/2072-6694/13/17/4279

Internet

https://www.mdpi.com/2072-6694/13/17/4279

Similar Items